Available option
10mg
Lyophilised powder
- Strength
- 10mg
- Format
- Lyophilised powder
Bear Biotech catalogue
Thymosin Alpha-1
Immunomodulatory thymic peptide research material
- Immune signalling
- T-cell research
- Disease-specific trials
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is Thymosin Alpha-1?
Thymosin Alpha-1 is an immunomodulatory thymic peptide with a much broader human research history than most compounds in the catalogue. Clinical studies span immune signalling and multiple disease contexts, but results are indication-specific and should not be generalised into a universal immune-benefit claim.
Human trials across several diseases; results are indication-specific and mixed
Research focus
Key research areas
Thymosin Alpha-1 research: immune signalling and thymic biology
Thymosin alpha-1 is a 28-amino-acid thymic peptide examined in immune-signalling studies. Human evidence varies by indication, formulation and study design. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- Immune signalling
- T-cell research
- Disease-specific trials
Representative primary research
Representative research
A multicentre double-blind phase-3 trial compared thymosin alpha-1 with placebo using prespecified outcomes.
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): a phase 3 trial ↗ The trial found no clear mortality difference; this link is neutral research context.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- Thymosin Alpha-1
- Research category
- Immunomodulatory thymic peptide research material
- Evidence position
- Human trials across several diseases; results are indication-specific and mixed
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Which immune and T-cell pathways are examined with Thymosin Alpha-1?
Thymosin Alpha-1 research focuses on immune signalling and T-cell biology across disease-specific models and trials. The relevant endpoint varies by indication.
Why must Thymosin Alpha-1 trial results remain disease-specific?
T-cell and immune-signalling findings must be interpreted within the disease, protocol and formulation studied. Results from one indication do not establish another.
What do mixed human trial results mean for a generic research vial?
Thymosin Alpha-1 has human trials across several diseases, with mixed and indication-specific results. A generic research vial is not an approved formulation.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.